News | Pediatric Cardiology | May 13, 2021

PolyVascular Awarded $2 Million Small Business Innovation Research Grant to Bring the First Polymer-Based Heart Valve for Children to Clinical Trials

Ultimate goal is to help 1 million pediatric patients with congenital heart disease around the world with more dependable and affordable solution

PolyVascular, leading the effort to improve children's lives with a novel polymeric transcatheter valve (PTV) for children, announced that it was awarded a $2 million Small Business Innovation Research (SBIR) Phase II grant earlier this year to bring its polymeric stent-mounted valve (SMV) to clinical trials within the next two years in an effort to address pediatric congenital heart disease (CHD), which affects over 1 million patients around the world.

May 13, 2021 — PolyVascular, leading the effort to improve children's lives with a novel polymeric transcatheter valve (PTV) for children, announced that it was awarded a $2 million Small Business Innovation Research (SBIR) Phase II grant earlier this year to bring its polymeric stent-mounted valve (SMV) to clinical trials within the next two years in an effort to address pediatric congenital heart disease (CHD), which affects over 1 million patients around the world.

As part of the next stage of growth for the company, PolyVascular named Will Clifton, M.D., as Chief Operating Officer (COO) to oversee the completion of the grant as Principal Investigator and to manage the operations and R&D for the company.

PolyVascular’s SMV is composed of polymer leaflets mounted within a metal stent that can be delivered via a minimally invasive transcatheter procedure, avoiding the risks of surgery, with potential for improved durability and function. Congenital heart disease remains the most common category of birth defect and a leading cause of childhood death in the developed world. Dysfunctional pulmonary valves (PV) are a common abnormality, and frequently require surgical intervention and replacement. Valve replacement through open heart surgery carries substantial risk and discomfort for pediatric patients, and represents a major financial and emotional burden for families. The most commonly used valves for pulmonary valve replacement in young children are biologically-derived (e.g. human cadaveric valves or biological tissue from animals), but are in short supply and have a tendency to not last very long, leading to repeat surgeries.

“Our aim at PolyVascular is to transform the care of children with congenital heart disease by developing an entirely new generation of valves made of medical grade polymer devoid of any biological tissue,” said Henri Justino, M.D., Chief Medical Officer, PolyVascular. “The valves in use so far for children have been made of biological tissue. Unfortunately, our immune systems target and destroy this biological tissue, sometimes rapidly, rendering the valve ineffective. PolyVascular’s approach will allow us to deliver these valves in a minimally invasive fashion, and extend the time between repeat surgeries. We are excited about our growth trajectory over the next few years, but we are more excited to make a difference in the lives of children with CHD and their families.”

Children age five and older will be eligible for the trans-catheter technology which will place the PTV device in the heart. The polymer valves last longer and can stay in the heart for longer versus biological valves which need to be replaced every few years as the child grows. When the polymer valves need to be replaced with larger sizes, the procedures will be done via catheter-based surgeries which save the patient from more invasive open-heart surgeries.

“I am very honored and excited to lead PolyVascular’s efforts to bring this brand new polymeric transcatheter valve to in-human trials within the next two years and then ultimately to the first pediatric patients,” said Will Clifton, M.D., COO of PolyVascular. “Our polymer-based valve will give pediatric patients around the world a greater quality of life as well as greater peace of mind for their families because of the durability of the valves.”

Clifton served as Sr. Director of Medical Affairs, at Procyrion, a clinical-stage medical device company in Houston. Will is also the President and co-founder of Enventure, a Houston medical innovation incubator and education hub. Will has also served as Director of Medical Innovation and lecturer at Rice University in the Department of Bioengineering and teaches the Biodesign Fellowship for TMC Innovation.

For more information: www.polyvascular.com

Related Content

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent. It is used for repair of sinus venosus atrial septal defects (SVASD). #SVASD #SCAI2021 #congenitalheart #

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent.

News | Congenital Heart | May 01, 2021
May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for interv
News | Congenital Heart | February 16, 2021
February 16, 2021 – In recognition of World...
The Smidt Heart Institute at Cedars-Sinai is working with the Keck Medicine of USC heart surgery team to expand care for children and adults with congenital heart disease. An echocardiographer helps with cardiac ultrasound imaging in a hybrid OR during a congenital case using a Siemens SC2000 imaging system. Photo by Cedars-Sinai.

The Smidt Heart Institute at Cedars-Sinai is working with the Keck Medicine of USC heart surgery team to expand care for children and adults with congenital heart disease. An echocardiographer helps with cardiac ultrasound imaging in a hybrid OR during a congenital case using a Siemens SC2000 imaging system. Photo by Cedars-Sinai.

News | Congenital Heart | August 10, 2020
August 10, 2020 - The...
Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects. #SCAI #SCAI2020

Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects.

News | Congenital Heart | May 21, 2020
May 21, 2020 — Two late-breaking clinical trials on trans catheter valves to treat congenital heart disease were pres
SCAI Issues Position Statement on Adult Congenital Cardiac Interventional Training, Competencies and Organizational Recommendations. A congenital atrial septal defect closed using a transcatheter occluder, visualized on 3-D TEE ultrasound.

A congenital atrial septal defect closed using a transcatheter occluder, visualized on 3-D TEE ultrasound.

News | Congenital Heart | May 04, 2020
University of Arizona Leads Statewide Study of Congenital Heart Defects
News | Congenital Heart | October 24, 2019
Investigators at the University of Arizona Steele Children's Research Center are leading a statewide study as part of a...
Abbott Receives European CE Mark for Two Pediatric Heart Devices
News | Congenital Heart | September 20, 2019
Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm rotatable mechanical heart...
High Blood Pressure, Cholesterol in Young Adults Associated With Later Heart Disease
News | Congenital Heart | July 16, 2019
Elevated blood pressure and cholesterol levels in young adulthood may lead to an increased risk of heart disease later...